The drug-eluting stent (DES) market has had quite the checkered past since the first generation DES technology was first introduced. Back in 2006, when the DAPT trial was initiated, concerns about the long-term safety of DES dominated med-tech headlines with some experts claiming that as many as 2,000 patients a year were dying needlessly as a result of the drug-coated devices (Medical Device Daily, Feb. 14, 2006). The rate of stent thrombosis (ST) was the primary concern surrounding DES at that time.